CVS Health Corporation $CVS Holdings Increased by State of Alaska Department of Revenue

State of Alaska Department of Revenue raised its position in CVS Health Corporation (NYSE:CVS) by 24.0% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 192,696 shares of the pharmacy operator’s stock after purchasing an additional 37,259 shares during the period. State of Alaska Department of Revenue’s holdings in CVS Health were worth $16,512,000 at the end of the most recent reporting period.

Other hedge funds have also recently made changes to their positions in the company. Turtle Creek Wealth Advisors LLC raised its position in shares of CVS Health by 43.8% in the third quarter. Turtle Creek Wealth Advisors LLC now owns 11,209 shares of the pharmacy operator’s stock worth $960,000 after buying an additional 3,414 shares in the last quarter. WealthPlan Investment Management LLC grew its position in CVS Health by 76.0% during the third quarter. WealthPlan Investment Management LLC now owns 3,470 shares of the pharmacy operator’s stock worth $297,000 after buying an additional 1,498 shares in the last quarter. Nvwm LLC grew its position in CVS Health by 12,778.8% during the third quarter. Nvwm LLC now owns 6,697 shares of the pharmacy operator’s stock worth $574,000 after buying an additional 6,645 shares in the last quarter. HBW Advisory Services LLC increased its stake in CVS Health by 3.5% in the 3rd quarter. HBW Advisory Services LLC now owns 3,408 shares of the pharmacy operator’s stock worth $292,000 after acquiring an additional 115 shares during the last quarter. Finally, Mather Group LLC. increased its stake in CVS Health by 41.2% in the 3rd quarter. Mather Group LLC. now owns 14,807 shares of the pharmacy operator’s stock worth $1,269,000 after acquiring an additional 4,319 shares during the last quarter. 80.66% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently commented on the stock. Robert W. Baird set a $107.00 price target on shares of CVS Health in a report on Thursday, August 6th. Weiss Ratings downgraded shares of CVS Health from a “buy (b-)” rating to a “hold (c+)” rating in a report on Friday, October 9th. Leerink Partners cut their target price on shares of CVS Health from $119.00 to $112.00 and set an “outperform” rating for the company in a research report on Monday. Bank of America raised their price target on CVS Health from $100.00 to $110.00 and gave the company a “buy” rating in a research report on Monday, June 22nd. Finally, Royal Bank Of Canada lifted their price target on CVS Health from $107.00 to $113.00 and gave the stock an “outperform” rating in a research note on Thursday, July 9th. Twenty analysts have rated the stock with a Buy rating and three have given a Hold rating to the company’s stock. Based on data from MarketBeat, CVS Health currently has a consensus rating of “Moderate Buy” and an average target price of $107.80.

CVS Health Trading Up 1.9%

CVS stock traded up $1.75 during trading on Thursday, hitting $92.14. 4,085,078 shares of the company traded hands, compared to its average volume of 8,330,671. The company has a 50-day moving average of $91.88 and a 200-day moving average of $92.87. The company has a debt-to-equity ratio of 0.74, a quick ratio of 0.66 and a current ratio of 0.87. CVS Health Corporation has a 1 year low of $69.51 and a 1 year high of $110.68. The firm has a market capitalization of $117.85 billion, a PE ratio of 24.38, a P/E/G ratio of 0.82 and a beta of 0.60.

CVS Health (NYSE:CVS) last released its quarterly earnings data on Wednesday, August 5th. The pharmacy operator reported $2.58 earnings per share for the quarter, beating analysts’ consensus estimates of $1.87 by $0.71. CVS Health had a return on equity of 13.12% and a net margin of 1.18%. The firm had revenue of $106.10 billion during the quarter, compared to analyst estimates of $100.03 billion. During the same quarter in the prior year, the firm posted $1.81 earnings per share. The business’s quarterly revenue was up 7.3% compared to the same quarter last year. CVS Health has set its FY 2026 guidance at 7.900-8.100 EPS. Analysts predict that CVS Health Corporation will post 8.02 earnings per share for the current fiscal year.

CVS Health Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Monday, November 2nd. Shareholders of record on Thursday, October 22nd will be given a $0.6650 dividend. The ex-dividend date is Thursday, October 22nd. This represents a $2.66 dividend on an annualized basis and a dividend yield of 2.9%. CVS Health’s payout ratio is presently 70.37%.

CVS Health News Summary

Here are the key news stories impacting CVS Health this week:

• Positive Sentiment: Analyst commentary highlighted CVS’s stronger returns, improving earnings estimates and lower valuation relative to Alignment Healthcare, while pointing to progress in Aetna’s turnaround. CVS vs. ALHC: Which Medicare Advantage Stock Is the Better Pick Now?
• Positive Sentiment: CVS opened its first pharmacy-focused location in the Boston area, aimed at improving access to medications, immunizations and pharmacy services in an underserved community. CVS Pharmacy Celebrates Opening of First Pharmacy-Focused Location in Boston Area
• Positive Sentiment: MinuteClinic received its seventh consecutive Joint Commission accreditation, supporting CVS’s strategy to expand primary-care services across its retail health network. MinuteClinic earns seventh consecutive Joint Commission accreditation
• Neutral Sentiment: CVS announced programs promoting at-home heart-rhythm monitoring through Signify Health and women’s midlife health research through The Midlife Collective. These initiatives could support long-term engagement but are unlikely to materially affect near-term earnings. CVS Health – Early Detection Matters
• Negative Sentiment: CVS agreed to pay $315 million to settle Justice Department allegations that its pharmacies improperly filled controlled-substance prescriptions and submitted false claims to federal healthcare programs. CVS admitted no wrongdoing and disputed the allegations, but the agreement includes enhanced prescription oversight and creates a reputational and compliance overhang. CVS Agrees to Pay $315M for Opioid Prescription Allegations

CVS Health Profile

CVS Health Corp. is an integrated health care company that provides pharmacy, insurance and health services primarily in the United States. Its operations are designed to connect consumers, health plans, health care providers and pharmacy services across multiple points of care.

The company’s major businesses include CVS Pharmacy retail locations, prescription fulfillment and consumer health products; CVS Caremark, a pharmacy benefit management business; and Aetna, which offers health insurance products and related services for employers, individuals, government programs and other organizations.